NeoBiocon and Abraxis BioScience, Inc have introduced Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the UAE for the treatment of breast cancer. The drug is recommended for those patients who have failed after combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy.
The details can be read here.
No comments:
Post a Comment